BUYINS.NET Updates OxySure Systems (OXYS) SqueezeTrigger Price and Market Maker Surveillance
- Approximately 6.48 Million Shares Shorted Since February 2012
- Short Squeeze Expected When Stock Crosses Above $0.82 SqueezeTrigger Price
FRISCO, TX--(Marketwired - June 09, 2015) - OxySure Systems, Inc. (OTC: OXYS) ("OxySure," or the "Company"), a global leader and innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology and other innovative medical device solutions, today announced that BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on OxySure Systems (OXYS) after releasing the latest short sale data through June 8, 2015. The total aggregate number of shares shorted since February 2012 is approximately 6.48 million shares. Approximately 35.62% of daily trading volume is short selling. The SqueezeTrigger price for all OXYS shares shorted is $0.82. A short squeeze is expected to begin when shares of OXYS close above the $0.82 SqueezeTrigger price.
Click here to view Report: http://www.buyins.com/reports/oxys6-8-15.pdf
Click here for SqueezeTrigger: http://www.buyins.com/images2/oxysstr6-8-15.jpg
Click here for Friction Factor: http://www.buyins.com/images2/oxysff6-8-15.jpg
Click here for detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of OXYS.42% of the previous 38 trading days have been positive or bullish-biased and 58% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors OXYS market-makers daily for compliance with Fair Market-Making Requirements.
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.
About OxySure Systems, Inc.
OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.
BUYINS.NET is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The Company has paid a non-affiliate $1,117 per month for three months of data provided in this report. OXYS has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Renmark Financial Communications, Inc.
Tel.: (416) 644-2020 or (514) 939-3989
Redchip Companies, Inc.
800-733-2447, ext. 107